13 June 2025

The quest for new treatment options for newborns with drug-resistant sepsis took another step forward this week with the enrollment of the first baby in a trial of a combination of three older antibiotics.

It is the second part of a clinical trial by the Global Antibiotic Research and  Development Partnership (GARDP) to evaluate various antibiotic combinations for newborn babies with sepsis.

The first part of the trial, called NeoSep1, was launched in 2023 and it tested two antibiotics – fosfomycin and flomoxef. In this part of the trial, a third antibiotic, amikacin, has been added to the first two antibiotics.